Pfizer, BioNTech to limit delays of vaccine shipments to one week

vaccine
Credit: Pixabay/CC0 Public Domain

Pfizer and BioNTech said Saturday they will limit the delays of their vaccine deliveries to just one week, after fears in Europe that shipments of the jabs could be slowed for up to a month.

The US drugmaker and its German partner "have developed a plan that will allow the scale-up of manufacturing capacities in Europe and deliver significantly more doses in the ," they said in a joint statement.

"As a result, our facility in Puurs, Belgium will experience a temporary reduction in the number of doses delivered in the upcoming week."

Pfizer and BioNTech pledged that deliveries would be back to the original schedule to the European Union from the week of January 25, with increased delivery from the week of February 15.

"To accomplish this, certain modifications of production processes are required now."

Pfizer had said Friday it would delay shipments of the jabs over the next three to four weeks due to works at its key plant in Belgium.

It said the modifications at the Puurs factory were necessary in order to ramp up its from mid-February.

In hard-hit Europe, the statement raised concerns that the delays could further slow a vaccine rollout that has already faced heavy criticism.

Six EU health ministers signed a letter to the European Commission on Friday to express "severe concern" over the delays.

The Pfizer-BioNTech vaccine, which was developed at record-breaking speed, became the first to be approved for general use by a Western country on December 2 when Britain gave it the go-ahead.


Explore further

Follow the latest news on the coronavirus (COVID-19) outbreak

© 2021 AFP

Citation: Pfizer, BioNTech to limit delays of vaccine shipments to one week (2021, January 16) retrieved 26 February 2021 from https://medicalxpress.com/news/2021-01-pfizer-biontech-limit-vaccine-shipments.html
This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no part may be reproduced without the written permission. The content is provided for information purposes only.
8 shares

Feedback to editors

User comments